前立腺性酸性フォスファターゼおよび前立腺特異抗原の免疫酵素測定法

Abstract

1)未治療前立腺癌33例で, PAPおよびPAの陽性率は, それぞれstage A10%, 25%, stage A20%, 0%, C pN050%, 50%, C NX 50%, 100%, D1 0%, 100%, D273%, 100%であった.2)組織学的に診断された前立腺肥大症でPAPが11.1%, PAが7.4%の異常値を示した.3)組織学的分化度とPAPならびにPAとの間に関連はなかった.4) PAPとPAとの間の相関係数は, 0.68と低値であった.5) Stage D2に対する内分泌療法後, 全例低下し, 治療効果をよく反映した.6)両マーカーとも, 再燃例は, 制癌例より有意に陽性の割合が高かった(p<0.01).また, PAPとPAの併用の意義が示された

Prostatic acid phosphatase (PAP) and prostatic specific antigen (PA) were determined with a Cetus test kit (California, USA) for prostatic cancer and others. Abnormal values of PAP in untreated prostatic cancer were found in 0, 0, 50, 50, 0, 73% of stage A1, A2, CpN0, CNX, D1 and D2 cases, respectively, and those of PA were found in 25, 0, 50, 100, 100, 100% of the same stages, respectively. Grade was not related to the level of PAP or PA. Prostatic hypertrophy showed increased values of PAP and PA in 11.1% and 7.4%, respectively. The levels of PAP were not correlated to those of PA. Endocrine treatment decreased the elevated values of PAP and PA in 60% of the cases. Most of the PAP and PA levels in the cases controlled under endocrine therapy were within normal values, but after relapse most showed elevated levels.